In a world where clarity drives change, the SOPHIA community is stepping forward with a unified voice. This consensus statement is also a strategic tool and messaging document that can help everyone speak consistently, clearly, and compellingly about the urgent need for personalised treatment pathways for people living with obesity.

Download the document and join us in shaping the future of obesity care

Why this matters

Obesity is not one condition — it is a spectrum of chronic, relapsing diseases. SOPHIA (Stratification of Obesity Phenotypes to Optimize Future Therapy) is working to change how obesity is understood and treated, moving toward tailored therapies that reflect its complexity.

About IMI SOPHIA

SOPHIA brings together a diverse alliance of academic institutions, industry leaders, patient organisations, and healthcare professionals to transform how obesity is understood and treated by identifying distinct obesity phenotypes and developing personalised treatment pathways.

Please contact Jacqueline Bowman (j.bowman@third-i.eu), Work Package Leader for Shared Value, to find out more and how you can work together to spread these important messages.

Jacqueline Bowman

Principal

Third-i bv

email: j.bowman@third-i.eu

Mob:+ 32 468 222 386

Visiting office:

The Library

10 Square Ambiorix

1000 Brussels

Belgium

SOPHIA has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 875534. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA and T1D Exchange, Breakthrough T1D (JDRF), and Obesity Action Coalition.